Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.
Kozakov D et al.
Frontiers in Medicine, 2025
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
The Clinicopathological Correlation of KRAS Mutation and PTEN Expression Status in Primary and Metastatic Colorectal Carcinoma.
Hassan RT et al.
Cureus, 2024
Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants.
Silverman I et al.
Frontiers in Molecular Biosciences, 2024
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T et al.
Cancer Medicine, 2023
RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.
Dorard C et al.
Oncogene, 2023
37020037 (PubMed )
Supplement: 41388_2023_2683_MOESM1_ESM.pdf
Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach.
S UK et al.
Journal of Biomolecular Structure & Dynamics, 2022
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K et al.
International Journal of Hematology, 2019
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
Hayama T et al.
International Journal of Colorectal Disease, 2019
Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.
Yilmaz A et al.
International Journal of Environmental Research and Public Health, 2014
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA et al.
Pancreas, 2012
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y et al.
Human Mutation, 2008
Select a paper to view details